Last C$51.87 CAD
Change Today +0.64 / 1.25%
Volume 327.0K
CCT On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ GS
Berlin
As of 4:00 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

catamaran corp (CCT) Snapshot

Open
C$51.31
Previous Close
C$51.23
Day High
C$52.05
Day Low
C$51.31
52 Week High
09/5/13 - C$59.24
52 Week Low
04/30/14 - C$40.52
Market Cap
10.8B
Average Volume 10 Days
381.5K
EPS TTM
C$1.36
Shares Outstanding
207.4M
EX-Date
--
P/E TM
34.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for CATAMARAN CORP (CCT)

catamaran corp (CCT) Related Businessweek News

No Related Businessweek News Found

catamaran corp (CCT) Details

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. The PBM services include electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail and specialty pharmacy claims management, Medicare Part D services, benefit design consultation, preferred drug management programs, drug review and analysis, consulting services, data access, and reporting and information analysis. It owns and operates a network of mail and specialty pharmacies. The HCIT solutions include RxCLAIM, an online transaction processing system to provide adjudication of third-party prescription drug claims at the point of service, as well as payment and billing support and real-time functionality for updating benefit, price, member, provider, and drug details. It also provides RxBUILDER, a Web-based interface for formulary creation and maintenance; RxPORTAL, which allows customers to interact with the patient’s formulary and drug history; and RxAUTH, a prior authorization (PA) management solution for automating PA process. In addition, the company offers RxMAX, a rebate management system designed to assist health plans in managing their relationships with pharmaceutical manufacturers; Zynchros, which provides a suite of formulary management tools; and RxTRACK, a data warehouse and analysis system. It serves various organizations in the pharmaceutical supply chain, such as federal, provincial, state and local governments, unions, corporations, pharmacy benefit managers, managed care organizations, retail pharmacy chains, and other healthcare intermediaries. The company was formerly known as SXC Health Solutions Corp. and changed its name to Catamaran Corporation in July 2012. Catamaran Corporation was founded in 1993 and is headquartered in Schaumburg, Illinois.

4,000 Employees
Last Reported Date: 03/3/14
Founded in 1993

catamaran corp (CCT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.0M
Executive Vice President of Operations
Total Annual Compensation: $635.0K
Executive Vice President of Pharmacy Operatio...
Total Annual Compensation: $450.0K
Executive Vice President of Quality & Innovat...
Total Annual Compensation: $320.0K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $310.0K
Compensation as of Fiscal Year 2013.

catamaran corp (CCT) Key Developments

Catamaran Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for Full Year 2014

Catamaran Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $5,385,808,000 against $3,417,430,000 a year ago. Operating income was $135,108,000 against $106,671,000 a year ago. Income before income taxes was $119,482,000 against $95,764,000 a year ago. Net income attributable to the company was $71,432,000 or $0.34 per diluted share against $63,421,000 or $0.31 per diluted share a year ago. Net cash provided by operating activities was $57,206,000 against $172,983,000 a year ago. Adjusted EBITDA was $196,943,000 against $131,148,000 a year ago. Purchases of property and equipment were $20,091,000 against $46,892,000 a year ago. Non-GAAP net income attributable to the company was $111,125,000 or $0.54 per diluted share against $100,639,000 or $0.49 per diluted share a year ago. EBITDA was $188,504,000 against $158,063,000 a year ago. For the six months, the company reported total revenues of $10,300,287,000 against $6,637,147,000 a year ago. Operating income was $251,897,000 against $197,520,000 a year ago. The increases in both periods are mainly due to organic growth driven by increased claim volume added through new customer implementations, including the continued implementation of the Cigna contract, as well as additional claim volume related to the Restat acquisition. Additionally, revenues have increased in both periods as a result of increased specialty claim volume, which carries a higher revenue per claim rate compared to the Company's general book of business. Income before income taxes was $224,935,000 against $175,574,000 a year ago. Net income attributable to the company was $134,877,000 or $0.65 per basic and diluted share against $114,826,000 or $0.56 per basic and diluted share a year ago. Net cash provided by operating activities was $192,886,000 against $236,253,000 a year ago. Adjusted EBITDA was $376,875,000 against $255,503,000 a year ago. Purchases of property and equipment were $32,873,000 against $72,135,000 a year ago. Non-GAAP net income attributable to the company was $214,820,000 or $1.04 per diluted share against $187,834,000 or $0.91 per diluted share a year ago. EBITDA was $359,353,000 against $301,602,000 a year ago. The company updated its 2014 full year financial guidance. For the year, the company expected adjusted diluted EPS in the range of $2.12 to $2.22 from the prior range of $2.10 to $2.22. Revenues are now estimated to be $20.5 to $21.0 billion versus the previous guidance of $20 to $21 billion. And GAAP diluted EPS is now expected to be $1.40 to $1.50 from $1.38 to $1.50 previously. EBITDA is expected to be between $770 million and $800 million and effective tax rate is expected to be closer to 28% for the full year of 2014.

Catamaran Corporation to Report Q2, 2014 Results on Aug 01, 2014

Catamaran Corporation announced that they will report Q2, 2014 results at 6:00 AM, US Eastern Standard Time on Aug 01, 2014

Catamaran Corporation, Q2 2014 Earnings Call, Aug 01, 2014

Catamaran Corporation, Q2 2014 Earnings Call, Aug 01, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCT:CN C$51.87 CAD +0.64

CCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioScrip Inc $8.31 USD -0.15
Cigna Corp $94.20 USD -0.40
Express Scripts Holding Co $73.45 USD -0.48
Walgreen Co $60.01 USD -0.51
WellPoint Inc $115.64 USD -0.87
View Industry Companies
 

Industry Analysis

CCT

Industry Average

Valuation CCT Industry Range
Price/Earnings 34.6x
Price/Sales 0.5x
Price/Book 1.9x
Price/Cash Flow 18.0x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CATAMARAN CORP, please visit www.catamaranrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.